In this issue:
Association of psoriatic microenvironment with treatment response
Ustekinumab for moderate-tosevere paediatric plaque psoriasis
Secukinumab in paediatric patients with severe chronic plaque psoriasis
Methotrexate and risk of cutaneous melanoma
Bimekizumab for moderate-tosevere plaque psoriasis
Four years of continuous guselkumab treatment for psoriasis
Time-to-relapse after tildrakizumab withdrawal
Guselkumab for pustulotic arthro-osteitis
Psoriatic arthritis in psoriasis patients on biologic therapy
Please login below to download this issue (PDF)